Osteoporosis

Osteoporosis is a systemic metabolic skeletal disorder characterized by decreased bone mineral density (BMD) and deterioration of bone microarchitecture, resulting in increased bone fragility and susceptibility to fracture.[1][2] The World Health Organization defines osteoporosis as a BMD T-score of −2.5 or lower at the hip or spine, as measured by dual-energy X-ray absorptiometry (DXA).[1][3] The pathogenesis centers on an imbalance between osteoclastic bone resorption and osteoblastic bone formation; in postmenopausal women, estrogen deficiency accelerates remodeling and net bone loss, while in aging men, reduced bone formation predominates.[4][5] The jaws are affected by the same systemic process, manifesting as thinning of the mandibular inferior cortex, altered trabecular architecture, and accelerated alveolar ridge resorption.[6][7] On panoramic radiography, the signature finding is erosion and thinning of the inferior mandibular cortex, which serves as a screening indicator for low systemic BMD.[8][9] Management is medical, directed by primary care or endocrinology, with the dental practitioner's role focused on recognition, referral, and awareness of treatment-related complications such as medication-related osteonecrosis of the jaw (MRONJ).[10][11]

The WHO classification recognizes four diagnostic categories based on DXA T-score:[1]

• Normal: T-score within 1 SD of the young adult reference mean
• Osteopenia (low bone mass): T-score between −1.0 and −2.5
• Osteoporosis: T-score of −2.5 or lower
• Severe (established) osteoporosis: T-score of −2.5 or lower with one or more fragility fractures

The term "osteopenia" describes a precursor state of reduced bone mass that does not meet the threshold for osteoporosis.[1][12] Older literature may use "senile osteoporosis" (type II) and "postmenopausal osteoporosis" (type I) to distinguish age-related from estrogen-deficiency-driven bone loss; current practice generally uses "primary osteoporosis" to encompass both.[2] Secondary osteoporosis refers to bone loss attributable to identifiable causes such as glucocorticoid use, hyperparathyroidism, or other endocrine disorders.[13][14]

• Prevalence: Globally, the pooled prevalence of osteoporosis is approximately 19.7% and osteopenia approximately 40.4%, with substantial regional variation. In the United States, osteoporosis affects approximately 10% of adults over 50 years, projected to reach 13.6% by 2030.[3][15][16]
• Sex: Women are disproportionately affected; approximately 20% of women over 50 and 30% of women 65 years or older meet DXA criteria, compared with approximately 4% of men over 50. An additional 40% of postmenopausal women have osteopenia.[3][4]
• Age: Prevalence increases sharply with age, from approximately 5% in adults aged 50–59 to over 26% in those 80 years and older.[3]
• Jaw involvement: The mandible, with its high proportion of cortical bone (up to 80%), demonstrates measurable cortical thinning and trabecular changes that correlate with systemic BMD, particularly in postmenopausal women. The maxilla, which is predominantly trabecular bone, may show density changes that correlate with lumbar and hip BMD.[17]

Osteoporosis is characteristically a silent disease with no symptoms until a fragility fracture occurs.[2][4] Oral and maxillofacial manifestations are subtle and nonspecific:

Oral findings

• Accelerated alveolar ridge resorption, particularly in edentulous patients, contributing to ill-fitting dentures[7][18]
• Association with increased severity of periodontal attachment loss and alveolar bone loss, though osteoporosis is considered a risk-modifying factor rather than a direct cause of periodontitis[17][19]
• Association with tooth loss, supported by most but not all studies; the relationship is confounded by socioeconomic and oral hygiene factors[17]
• Delayed alveolar bone healing following tooth extraction[7][20]

Systemic presentation

• Fragility fractures of the hip, vertebrae, and wrist are the principal clinical consequences[1][4]
• Height loss (≥4 cm from early adult height or ≥2 cm within 3 years) suggests asymptomatic vertebral compression fracture[21]
• Approximately 50% of postmenopausal women will sustain a fragility fracture in their lifetime[4]

Red flags for the dental practitioner

• Postmenopausal women or men over 70 with clinical risk factors (low BMI, glucocorticoid use, smoking, parental hip fracture history, excessive alcohol) warrant consideration for BMD screening referral[12][22]
• Patients on antiresorptive therapy (bisphosphonates, denosumab) require awareness of MRONJ risk, particularly before invasive dental procedures[10][11]

The radiographic findings of osteoporosis in the jaws are generalized and bilateral, reflecting a systemic metabolic process rather than a focal lesion. Dental radiographs do not diagnose osteoporosis but can identify features that warrant referral for DXA evaluation.[6][8][9]

Location and distribution

• Changes are generalized, affecting both jaws, though the mandible is more readily assessed due to its thick inferior cortex and visibility on panoramic radiography[6][17]
• The maxilla, being predominantly trabecular bone, may show density changes but is less reliably evaluated on conventional radiographs[17]
• Alveolar bone loss is most apparent in edentulous regions and interradicular septa[17][18]

Inferior mandibular cortex

The inferior mandibular cortex is the most extensively studied and clinically useful site for osteoporosis screening on panoramic radiography.[6][8][9]

• Mandibular cortical index (MCI/Klemetti index): A qualitative classification of the inferior cortical morphology:[8][9][23]
  • C1: endosteal margin is even and sharp (normal)
  • C2: endosteal margin shows semilunar defects or cortical residues (mildly to moderately eroded)
  • C3: cortical layer is clearly porous with heavy endosteal residues (severely eroded)
• C2 and C3 morphologies are associated with reduced systemic BMD. The presence of cortical erosion (C2 or C3) has a pooled sensitivity of approximately 0.79 and specificity of approximately 0.56 for detecting reduced BMD.[8]
• Mandibular cortical width (MCW): Measured at the mental foramen region; a width greater than 4 mm is associated with normal BMD in most cases, while a width of 3 mm or less raises concern for osteoporosis. MCW ≤3 mm combined with a FRAX score >15% improves diagnostic accuracy substantially.[8][9][24]
• Panoramic mandibular index (PMI): The ratio of mandibular cortical width to the distance from the inferior mandibular cortex to the inferior border of the mental foramen; a cutoff of 0.3 yields moderate sensitivity and specificity.[8]

Internal architecture (trabecular bone pattern)

• Osteoporotic trabecular changes in the jaws include widened marrow spaces, thinned trabeculae, and reduced trabecular connectivity, mirroring changes in the axial skeleton[5][25]
• Mandibular trabecular bone pattern becomes more spaced and less connected with advancing age in most women; this pattern is better preserved in men[17]
• Trabecular pattern changes are more closely related to systemic fracture risk than cortical width measurements[17]
• Fractal dimension analysis of trabecular bone on dental radiographs has been investigated as a screening tool, with pooled sensitivity of approximately 86% and specificity of approximately 73%, though evidence remains heterogeneous and the method is not yet standardized for clinical use[26][27]

Effects on teeth and adjacent structures

• Increased alveolar crest height loss, particularly in the presence of coexisting periodontal disease[17]
• No direct effect on tooth structure (no resorption of teeth, no displacement)
• Widened periodontal ligament space is not a characteristic feature

Cortical involvement and extent

• Generalized cortical thinning throughout the mandible, most measurable at the inferior border[6][9]
• Increased cortical porosity, particularly at the endosteal surface[5][25]
• Cross-sectional imaging demonstrates reduced cortical thickness at multiple mandibular sites (symphysis, molar, and posterior regions), with the molar and posterior regions showing the most consistent correlation with DXA-confirmed osteoporosis[28]

Volumetric assessment

• CBCT-derived indices—including the computed tomography cortical index (CTCI), CT mental index (CTMI), and CT mandibular index (CTI)—correlate with DXA-measured BMD and may serve as adjunctive screening tools[29][30]
• Radiographic density measurements and regional cortical thickness indices on CBCT show strong correlation with systemic BMD[29][31]
• Morphometric parameters for trabecular bone on CBCT have not consistently shown differences between osteoporotic and non-osteoporotic patients, limiting their current utility[29]

DXA (dual-energy X-ray absorptiometry)

DXA of the hip and lumbar spine remains the gold standard for diagnosing osteoporosis and is the basis for the WHO T-score classification.[1][12][22] It is not a dental imaging modality but is the definitive test to which dental radiographic screening indices are compared.

Medical CT

Quantitative computed tomography (QCT) measures volumetric BMD and can assess trabecular and cortical bone compartments separately, but it is primarily a research tool with higher radiation dose than DXA.[32] Medical CT may also identify incidental vertebral compression fractures or other skeletal manifestations of osteoporosis not visible on dental imaging.

MRI

MRI can evaluate bone marrow composition and trabecular microarchitecture without ionizing radiation. Increased marrow fat content on MRI correlates with reduced BMD and may provide complementary information, though MRI is not routinely used for osteoporosis diagnosis.[33]

Nuclear medicine

Bone scintigraphy is not used for osteoporosis diagnosis but may identify occult fractures or help distinguish osteoporotic compression fractures from pathologic fractures due to metastatic disease.[33]

The radiographic changes of osteoporosis in the jaws—generalized reduced bone density, cortical thinning, and altered trabecular pattern—overlap with several other metabolic and systemic conditions. The key distinguishing feature of osteoporosis is its generalized, bilateral, symmetric nature without focal lytic or sclerotic lesions.

The highest-risk diagnostic pitfall is failing to recognize hyperparathyroidism masquerading as osteoporosis, as both produce generalized demineralization. When a giant cell lesion of the jaw is identified histologically, serum calcium and parathyroid hormone levels should be obtained to exclude hyperparathyroidism, which requires fundamentally different management.[34][39]

Osteoporotic bone is characterized by quantitative reduction in bone mass with preservation of normal mineralization, distinguishing it from osteomalacia where mineralization is impaired.[1][5]

Microscopic findings

• Trabecular bone: Thinning and loss of trabeculae with widened marrow spaces; loss of trabecular connectivity with conversion from plate-like to rod-like architecture[5][25][40]
• Cortical bone: Reduced cortical thickness with increased intracortical porosity from enlarged Haversian canals and incompletely closed remodeling units; endocortical resorption further thins the cortex[5][41]
• Bone quality: The remaining bone is normally mineralized with normal lamellar architecture; there is no abnormal osteoid accumulation (unlike osteomalacia)[1][25]

Jaw-specific findings

• Animal models demonstrate that estrogen deficiency produces trabecular thinning, increased trabecular separation, and reduced bone volume fraction in both mandibular and maxillary alveolar bone[20][42]
• Osteocyte lacunar-canalicular networks in the mandible show reduced connectivity and impaired intercellular communication in osteoporotic states[43]
• Periodontal ligament atrophy with reduced osteoprogenitor cell pools has been demonstrated in osteoporotic animal models, correlating with delayed extraction socket healing[20]

Radiologic-pathologic correlation

The cortical erosion patterns classified by the Klemetti index (C1–C3) on panoramic radiography correspond histologically to progressive endosteal resorption and increased cortical porosity.[6][44] The generalized radiolucency seen on dental radiographs reflects the combined effect of trabecular thinning and cortical bone loss rather than replacement by pathologic tissue.

Role of the dental practitioner

The dental practitioner serves a screening and referral role rather than a diagnostic or therapeutic one:[6][17]

• Evaluate the inferior mandibular cortex on panoramic radiographs in at-risk patients (postmenopausal women, elderly men, patients with risk factors)
• Refer patients with cortical erosion (MCI C2/C3) or reduced mandibular cortical width (≤3 mm) for DXA evaluation by their primary care physician[8][9][24]
• Maintain awareness that dental radiographic indices are screening tools, not diagnostic methods[9]

Systemic diagnosis and treatment

• DXA of the hip and lumbar spine establishes the diagnosis; FRAX calculates 10-year fracture probability to guide treatment decisions[4][12][22]
• Pharmacologic treatment is recommended for patients with a T-score ≤−2.5, a fragility fracture, or high FRAX-estimated fracture risk (≥3% hip or ≥20% major osteoporotic fracture)[2][4]
• Antiresorptive agents: Bisphosphonates (alendronate, risedronate, zoledronic acid) and denosumab reduce fracture risk and are first-line for high-risk patients[2][4]
• Anabolic agents: Teriparatide, abaloparatide, and romosozumab are preferred initial therapy for very high-risk patients, followed by antiresorptive consolidation[2][4]

Dental management considerations

• MRONJ risk: The absolute risk of MRONJ in osteoporosis patients on antiresorptive therapy is estimated at 0.001%–0.01%, substantially lower than in oncology patients. Risk increases with duration of therapy beyond 4 years.[10][11]
• Before invasive dental procedures: The American Association of Oral and Maxillofacial Surgeons recommends a 2-month drug holiday for patients on bisphosphonates for more than 4 years before surgical procedures; the American Dental Association does not recommend routine discontinuation. If antiresorptive therapy has not yet been initiated, deferral until dental surgical sites have healed is reasonable.[10]
• Dental implants: Osteoporosis is not a contraindication for dental implant placement; survival rates exceed 90% and are comparable to those in non-osteoporotic patients, though cautious planning and potentially longer healing periods may be warranted.[45][46][47]
• Routine dental care and optimization of oral hygiene are important for MRONJ prevention in patients on antiresorptive therapy.[10][11]

Prognosis

Osteoporosis is a chronic, progressive condition. Untreated, approximately 50% of postmenopausal women will sustain a fragility fracture.[4] Hip fractures carry a one-year mortality of approximately 21–24%.[2][16] Pharmacologic treatment significantly reduces fracture risk, and early detection through screening—including opportunistic dental radiographic assessment—can facilitate timely intervention.[17][22]

Medication-related osteonecrosis of the jaw (MRONJ)

MRONJ is defined as exposed bone or bone probeable through an intraoral or extraoral fistula persisting for more than 8 weeks in a patient with current or previous antiresorptive or antiangiogenic therapy, without a history of radiation to the jaws.[10][11] In osteoporosis patients:

• The incidence is rare (0.001%–0.01%), far lower than in oncology patients receiving high-dose antiresorptive therapy (1%–15%)[11][48]
• Risk factors include duration of antiresorptive therapy, invasive dental procedures (especially extractions), poor oral hygiene, glucocorticoid use, diabetes, and ill-fitting dentures[11]
• Staging guides management: conservative therapy (antibacterial rinses, systemic antibiotics) for stages 0–2; surgical debridement or resection for stage 3[10][49]
• Teriparatide may facilitate healing of MRONJ lesions in osteoporosis patients without contraindications[11][48]

Glucocorticoid-induced osteoporosis

Chronic glucocorticoid use is a common cause of secondary osteoporosis and an independent risk factor for both fractures and MRONJ.[13][14] Patients on long-term glucocorticoids warrant earlier BMD screening and may require pharmacologic osteoporosis treatment at higher T-score thresholds than primary osteoporosis.[10]